Mayo Clinic Laboratory and Pathology Research Roundup: Aug. 20

By Kelley Luedke • August 20, 2018

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis

It is unclear how long pancreatic ductal adenocarcinomas (PDACs) are present before diagnosis. Patients with PDAC usually develop hyperglycemia and diabetes before the tumor is identified. If early invasive PDACs are associated with hyperglycemia, the duration of hyperglycemia should associate with the time that they have had the tumor. Mayo Clinic researchers collected data on patients with PDACs from medical databases in Olmsted County, Minnesota, from 2000 through 2015 and from the Mayo Clinic's tumor registry from January 1, 1976, through January 1, 2017. They compared glycemic profiles of patients with PDAC (cases) compared with patients without cancer, matched for age and sex. Researchers analyzed temporal fasting blood glucose (FBG) profiles collected for 60 months before patients received a PDAC diagnosis. FBG profiles of patients with resected PDAC stratified by tumor volume and grade, and temporal FBG profiles of patients with resected PDACs from whom long-term FBG data were available. The primary outcome was to estimate duration of presence of invasive PDAC before its diagnosis based on hyperglycemia, defined as significantly higher FBG levels in cases compared with controls. In a case-control study of patients with PDAC from 2 databases, researchers associated FBG level with time to PDAC diagnosis and tumor volume and grade. Patients are hyperglycemic for a mean period of 36 to 30 months before PDAC diagnosis; this information might be incorporated into strategies for early detection. The study was published in Gastroenterology.

Published to PubMed This Week

• • • • • Molecular Profiling Reveals Immunogenic Cues in Anaplastic Large Cell Lymphomas with DUSP22 Rearrangements
          Blood
        • Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
          Journal of the National Cancer Institute
        • A Patient With Hereditary ATTR and a Novel AGel p.Ala578Pro Amyloidosis
          Mayo Clinic Proceedings
        • MASS-FIX May Allow Identification of Patients at Risk for Light Chain Amyloidosis Before the Onset of Symptoms
          American Journal of Hematology
        • Splenectomy in Patients with Chronic Myelomonocytic Leukemia: Indications, Histopathological Findings and Clinical Outcomes in a Single Institutional Series of 39 Patients
          American Journal of Hematology
        • Non-Invasive Visualization of Tumor Infiltrating Lymphocytes in Patients with Metastatic Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Pilot Study
          Oncotarget
        • Prognostic Evaluation of Perinephric Fat, Renal Sinus Fat, and Renal Vein Invasion for Patients with Pathologic Stage T3a Clear Cell Renal Cell Carcinoma
          BJU International
        • Incidence, Prevalence, Mortality and Chronic Renal Damage of Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis in a 20-Year Population-Based Cohort
          Nephrology Dialysis Transplantation
        • Diagnostic Concordance Between NT-proBNP and BNP for Suspected Heart Failure
          Clinical Biochemistry
        • Aging and the Immune System: An Overview
          Journal of Immunological Methods

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.